<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName nlm2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9510844</article-id><article-id pub-id-type="publisher-id">958012</article-id><article-id pub-id-type="doi">10.3389/fphar.2022.958012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The microbiome-product colibactin hits unique cellular targets mediating host&#x02013;microbe interaction</article-title><alt-title alt-title-type="left-running-head">Mousa</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2022.958012" ext-link-type="uri">10.3389/fphar.2022.958012</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mousa</surname><given-names>Walaa K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/731422/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>College of Pharmacy</institution>, <institution>Al Ain University</institution>, <addr-line>Abu Dhabi</addr-line>, <country>United Arab Emirates</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>College of Pharmacy</institution>, <institution>Mansoura University</institution>, <addr-line>Mansoura</addr-line>, <country>Egypt</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/491667/overview" ext-link-type="uri">Fareeha Anwar</ext-link>, Riphah International University (Lahore), Pakistan</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/1396686/overview" ext-link-type="uri">Irum Shahzadi</ext-link>, COMSATS University Islamabad, Pakistan</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/394405/overview" ext-link-type="uri">Jun-Seob Kim</ext-link>, Incheon National University, South Korea</p></fn><corresp id="c001">*Correspondence: Walaa K. Mousa, <email>walaa.mousa@aau.ac.ae</email>
</corresp><fn fn-type="other"><p>This article was submitted to Predictive Toxicology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><elocation-id>958012</elocation-id><history><date date-type="received"><day>31</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2022 Mousa.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Mousa</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The human microbiota produces molecules that are evolved to interact with the diverse cellular machinery of both the host and microbes, mediating health and diseases. One of the most puzzling microbiome molecules is colibactin, a genotoxin encoded in some commensal and extraintestinal microbes and is implicated in initiating colorectal cancer. The colibactin cluster was discovered more than 15&#x000a0;years ago, and most of the research studies have been focused on revealing the biosynthesis and precise structure of the cryptic encoded molecule(s) and the mechanism of carcinogenesis. In 2022, the Balskus group revealed that colibactin not only hits targets in the eukaryotic cell machinery but also in the prokaryotic cell. To that end, colibactin crosslinks the DNA resulting in activation of the SOS signaling pathway, leading to prophage induction from bacterial lysogens and modulation of virulence genes in pathogenic species. These unique activities of colibactin highlight its ecological role in shaping gut microbial communities and further consequences that impact human health. This review dives in-depth into the molecular mechanisms underpinning colibactin cellular targets in eukaryotic and prokaryotic cells, aiming to understand the fine details of the role of secreted microbiome chemistry in mediating host&#x02013;microbe and microbe&#x02013;microbe interactions. This understanding translates into a better realization of microbiome potential and how this could be advanced to future microbiome-based therapeutics or diagnostic biomarkers.</p></abstract><kwd-group><kwd>colibactin</kwd><kwd>phage induction</kwd><kwd>genotoxicity</kwd><kwd>human microbiome</kwd><kwd>colorectal cancer</kwd><kwd>inflammation</kwd><kwd>colitis</kwd><kwd>DNA damage</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Trillions of microbes reside in the human gut interacting with each other and the outcome of their interaction affects human health and diseases (<xref rid="B66" ref-type="bibr">Sharon et al., 2014</xref>; <xref rid="B18" ref-type="bibr">Dhanaraju and Rao 2022</xref>; <xref rid="B17" ref-type="bibr">de Vos et al., 2022</xref>). This interaction is mediated by evolved small molecules, of which the vast majority are still dark matter (<xref rid="B82" ref-type="bibr">Wilson, Zha, and Balskus 2017</xref>; <xref rid="B84" ref-type="bibr">Zha et al., 2022</xref>). A few examples of microbiome secreted products are reported, each with a unique activity such as the microbial genotoxin colibactin (<xref rid="B79" ref-type="bibr">Wernke et al., 2020</xref>). Colibactin is a hybrid polyketide&#x02013;non-ribosomal peptide product encoded in the genome of some Enterobacteriaceae that belong to the phylogenetic group B. Colibactin is implicated in causing colorectal cancer (CRC) by inducing a signature mutation in DNA. Isolation and structural elucidation of colibactin has challenged the scientific field for over 15 years because of its contact-dependent synthesis, minimal expression, and chemical instability. The bulk of the research study on colibactin is centered around revealing its structure, mainly through bioinformatic analysis, comparative metabolomics, and mutational studies (<xref rid="B68" ref-type="bibr">Tang et al., 2022</xref>). However, to appreciate the evolved function of colibactin(s) and other microbiome products, we must understand their ecological role in enhancing the competency and fitness of producers. There are some reports on the antimicrobial-like activity of colibactin, but most of the data come from observational or associational studies without revealing the underpinning mechanism of action (T. <xref rid="B21" ref-type="bibr">Fa&#x000ef;s et al., 2016</xref>). In a pioneering study, the group of Dr. Balskus revealed that colibactin induces prophage activation on a wide scale in multiple phage&#x02013;bacteria systems. This activity is mediated by its ability to damage DNA activating the SOS response. Moreover, induction of prophages affects prophage-encoded genes such as some bacterial toxins, which are crucial for their pathogenicity. This finding reveals another interesting role of colibactin in mediating microbe&#x02013;microbe interaction and shaping the structure of gut microbes (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>; <xref rid="B72" ref-type="bibr">Tronnet et al., 2020</xref>).</p><p>Our knowledge of colibactin(s) is developing and there are previous reviews covering their prospective research period (<xref rid="B22" ref-type="bibr">Fa&#x000ef;s et al., 2018</xref>; <xref rid="B7" ref-type="bibr">Bode 2015</xref>; <xref rid="B4" ref-type="bibr">Balskus 2015</xref>; <xref rid="B80" ref-type="bibr">Williams et al., 2020</xref>; <xref rid="B79" ref-type="bibr">Wernke et al., 2020</xref>; <xref rid="B68" ref-type="bibr">Tang et al., 2022</xref>). These reviews mainly focused on summarizing advances in understanding possible biosynthetic pathways, bioinformatic prediction of colibactin and precolibactin structures, and the mechanism of DNA mutation. In this review, we analyze the unique cellular targets of colibactin(s) mediating host&#x02013;microbe interactions that shape gut microbiome structures and influence host&#x02019;s health. We discuss the molecular mechanisms underlying the evolved function of colibactin in hitting multiple targets in both the eukaryotic and prokaryotic cell machinery. We propose a mechanistic model for the series of events leading to colibactin-induced cancer. This knowledge is central to better advancing the use of microbiome secreted products or genes as diagnostic biomarkers or therapeutic interventions.</p></sec><sec id="s2"><title>The latest development in understanding the biosynthesis and structure of colibactin(s)</title><sec id="s2-1"><title>Prevalence and significance of colibactin gene cluster in prokaryotes</title><p>The first report on the colibactin cluster is dated back to 2006 when <ext-link xlink:href="https://pubmed.ncbi.nlm.nih.gov/?term=Nougayr%C3%A8de+JP&#x00026;cauthor_id=16902142" ext-link-type="uri">Nougayr&#x000e8;de</ext-link> et al. <xref rid="B56" ref-type="bibr">(2006</xref>) reported the discovery of <italic>Escherichia coli</italic> strains belonging to the phylogenetic group B2 that can block mitosis, leading to megalocytosis and eventually cell death. The authors linked this weird activity to a genomic island that encodes cryptic molecule(s), named at this time colibactin (<xref rid="B56" ref-type="bibr">Nougayr&#x000e8;de et al., 2006</xref>). Interestingly, this gene cluster is prevalent in gut microbes, in particular Group B of human-associated strains of <italic>E. coli</italic> and Enterobacteriaceae, including commensal and probiotic strains such as <italic>E. coli</italic> Nissle 1917, a commercial probiotic (Mutaflor) used to improve gastrointestinal inflammatory conditions such as ulcerative colitis (<xref rid="B63" ref-type="bibr">Schultz 2008</xref>). The Colibactin cluster is also sequenced from other non-human associated microbes such as <italic>Pseudovibrio</italic> sp. JE062, isolated from a marine sponge (<xref rid="B8" ref-type="bibr">Bondarev et al., 2013</xref>) and a novel strain of <italic>Erwina oleae</italic> sp. isolated from olive tree nots caused by <italic>Pseudomonas savastanoi</italic> (<xref rid="B53" ref-type="bibr">Moretti et al., 2011</xref>). The <italic>Frischella perrara</italic> PEB0191 is a commensal gut microbe in honey bees. The Crawford group showed that <italic>F. perrara</italic> PEB0191 produces colibactin mimics and induces DNA breaks similar to human microbiome strains (<xref rid="B20" ref-type="bibr">Engel, Vizcaino, and Crawford 2015</xref>). This widespread prevalence of colibactin or its homologs indicates its potential role in a symbiotic relationship, which likely confers beneficial outcomes to the host.</p></sec><sec id="s2-2"><title>Genomic organization of the colibactin cluster</title><p>The colibactin cluster encodes 54-kb hybrid nonribosomal peptide synthetase-polyketide synthase (NRPS-PKS) biosynthetic genes known as the <italic>pks or clb</italic> gene cluster (<xref rid="F1" ref-type="fig">Figure 1</xref>). The cluster consisted of 19 genes, named alphabetically, clb A-S. These 19 genes encode three polyketide synthases (PKSs), three nonribosomal peptide synthases (NRPSs), two hybrids NRPS/PKS, MATE transporter, resistance gene, and other nine tailoring and accessory enzymes as per the latest update as reviewed (<xref rid="B68" ref-type="bibr">Tang et al., 2022</xref>). Intensive research reports confirm that all of these genes are essential for genotoxicity, except for clb M, S, and R (<xref rid="B56" ref-type="bibr">Nougayr&#x000e8;de et al., 2006</xref>). Our current understanding of colibactin structure is shaped through understanding the organization of its biosynthetic genes, mutational studies, heterologous expression, and structure prediction using bioinformatics models. Over the last 16 years, there have been multiple hypotheses for the biosynthesis of colibactin, and the most recent is the prodrug activation theory (<xref rid="F1" ref-type="fig">Figure 1</xref>) developed by the Balskus group (<xref rid="B11" ref-type="bibr">Brotherton and Balskus 2013</xref>; <xref rid="B4" ref-type="bibr">Balskus 2015</xref>). The genomic island of colibactin contains the <italic>clbP</italic> gene, which is a peptidase enzyme that shares structure/function homology with cleavage enzymes functioning in ribosomaly synthesized posttranslational modified peptides such as ZmaM in zwittermicin biosynthesis (<xref rid="B47" ref-type="bibr">Luo et al., 2011</xref>). This similarity is revealed by a plethora of confirmation analyses, including structure&#x02013;activity relationship, crystallography, and mutagenesis (<xref rid="B16" ref-type="bibr">Cougnoux et al., 2012</xref>; <xref rid="B19" ref-type="bibr">Dubois et al., 2011</xref>). This fact leads Balskus and coworkers to hypothesize the prodrug activation theory for the biosynthesis of colibactin in which two NRPS modules (clbN and clbB) install the N-acyl-<sc>d</sc>-asparagine scaffold earlier in the biosynthesis, followed by clbP cleaving the amide bond and releasing the final active colibactin product (<xref rid="B11" ref-type="bibr">Brotherton and Balskus 2013</xref>). The Muller group added additional verification of the hypothesis by isolating the hypothesized prodrug from <italic>E. coli</italic>-Nissle 1917 (<xref rid="B5" ref-type="bibr">Bian et al., 2013</xref>). Further studies revealed that silencing of this peptidase enzyme (&#x00394; clbP strain) facilitates the accumulation of precolibactins, which are more stable derivatives of the main genotoxic molecule. &#x00394; clbP strains have a diminished genotoxic activity compared to wild type. Of note, we still lack more precise information on the genetic organization of colibactin-like clusters in other species and how the possible polymorphism might lead to functionally diverse molecules.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>Genetic organization and possible biosynthesis of colibactin. <bold>(A)</bold> Organization of the biosynthetic genes cluster of colibactin. <bold>(B)</bold> Prodrug activation hypothesis overview shows the last required step for production of the genotoxin, which is catalyzed by peptidase enzyme.</p></caption><graphic xlink:href="fphar-13-958012-g001" position="float"/></fig></sec><sec id="s2-3"><title>Revealing the structure of colibactin derivatives (precolibactins)</title><p>The precise structure of the colibactin molecule has remained unknown for over a decade. Purification of colibactin from native or heterologous hosts is challenging due to its minimal production upon fermentation, instability, and contact or inflammation-dependent gene expression. To overcome this challenge, several research groups developed alternative strategies to characterize the more stable derivatives or precursors of colibactin, named precolibactins (<xref rid="B75" ref-type="bibr">Vizcaino et al., 2014</xref>; <xref rid="B42" ref-type="bibr">Li et al., 2019</xref>; <xref rid="B74" ref-type="bibr">Vizcaino and Crawford 2015</xref>; <xref rid="B12" ref-type="bibr">Brotherton et al., 2015</xref>; <xref rid="B6" ref-type="bibr">Bian et al., 2015</xref>; <xref rid="B44" ref-type="bibr">Li et al., 2015</xref>; <xref rid="B43" ref-type="bibr">Li et al., 2016</xref>; <xref rid="B28" ref-type="bibr">Healy, Vizcaino, et al., 2016b</xref>). These strategies involve: 1) mutating the <italic>clbP</italic> gene, an essential enzyme required to produce active genotoxic colibactin molecules, and the generation of a series of other mutants; 2) heterologous expression of the mutated gene clusters; 3) comparative metabolomic analysis of mutants and wild-type strains; 4) tandem MS&#x02013;MS fragmentation analysis coupled with isotopic feeding experiments; and 5) synthesis of potential precolibactin analogues. Following these approaches, around 40 precolibactins have been predicted, isolated, or synthesized. Some structurally unique examples of precolibactins are shown in <xref rid="F2" ref-type="fig">Figure 2</xref>. Isolated or predicted precolibactins might be biosynthetically related, and for example, theoretically, precolibactin C could be biosynthesized from A via cyclodehydration as proposed (Healy 2017). Healy et al. proposed that precolibactins A-C may not be the precursors for colibactin as previously thought but rather alternative products produced only when the cibP is nonfunctional by a double cyclodehydration pathway (<xref rid="B27" ref-type="bibr">Healy et al., 2016a</xref>; <xref rid="B28" ref-type="bibr">Healy et al., 2016b</xref>). This hypothesis is based on some evidence that colibactin alkylates DNA by the formation of unsaturated imines, which could not be generated from the pyridone ring in precolibactins A-C (<xref rid="B27" ref-type="bibr">Healy et al., 2016a</xref>). Interestingly, some precolibactins share a structural similarity with yatakemycin and duramycin, mainly the aminocyclopropane moiety, which attacks DNA via nucleophilic ring-opening (<xref rid="B70" ref-type="bibr">Tichenor and Boger 2008</xref>). Precolibactin A weakly cross-links DNA <italic>in vitro</italic> while a precolibactin derivative lacking the spiro bicyclic structure was inactive (<xref rid="B74" ref-type="bibr">Vizcaino and Crawford 2015</xref>). Further evidence suggests that the two precolibactins isolated are products of the intact colibactin cluster.</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>Selected examples of precolibactins with unique structures.</p></caption><graphic xlink:href="fphar-13-958012-g002" position="float"/></fig></sec><sec id="s2-4"><title>Revealing the structure of colibactin(s)</title><p>In 2019, the Qian group elucidated the structure of a colibactin molecule based on <italic>in vitro</italic> cleavage of an isolated precolibactin with an MWT of 969 to yield colibactin with an MWT of 645 (<xref rid="B42" ref-type="bibr">Li et al., 2019</xref>). Further evidence confirms that this structure is produced from the native PKS + strain. This evidence includes the presence of the product in the extract of native colibactin-harboring <italic>E. coli</italic> CFT073 as detected by MS&#x02013;MS analysis and the ability of the compound to induce the characteristic DNA double-strand breaks (<xref rid="B42" ref-type="bibr">Li et al., 2019</xref>). In the same year, Crawford/Herzon and Balskus groups independently elucidated the structure of another colibactin molecule with an MWT of 770 and validated its genotoxic activity (<xref rid="B83" ref-type="bibr">Xue et al., 2019</xref>; <xref rid="B34" ref-type="bibr">Jiang et al., 2019</xref>). Crawford/Herzon predicted the structure by a DNA adductome approach followed by total synthesis. The Balskus group predicted the structure by studying <italic>clbP</italic>/<italic>clbL</italic> double mutants, labeling experiments, and an adductome approach. The clbL is predicted to encode amidase functions by hydrolysis of an amide bond; however, the authors validated that this enzyme is rather the final step in the production of intact precolibactin (<xref rid="B34" ref-type="bibr">Jiang et al., 2019</xref>). In 2022, the Watanabe group isolated a colibactin molecule with an MWT of 788 from the <italic>pks + E. coli</italic> strain-50, a strain isolated from colorectal cancer tissues that produces 26-fold more colibactin than Nissle 1917 (<xref rid="B30" ref-type="bibr">Hirayama et al., 2019</xref>; <xref rid="B85" ref-type="bibr">Zhou et al., 2021</xref>). Of note, the same group has developed an activity-based fluorescent probe to identify high colibactin producers from clinical samples 3 years before elucidating the first-isolation-based structure of colibactin (<xref rid="B30" ref-type="bibr">Hirayama et al., 2019</xref>). At first, the authors obtained two fragments of the compound whose structures are suggestive of spontaneous hydrolysis of the candidate molecule at the 1,2-diketone moiety as previously described by the Herzon group (<xref rid="B29" ref-type="bibr">Healy et al., 2019</xref>). Next, they managed to protect the compound from hydrolysis by adding <italic>o</italic>-phenylenediamine to convert the 1,2-diketone moiety into quinoxaline, which is not subjected to hydrolysis and isolated a few micrograms of colibactin sufficient for further NMR spectroscopic analysis (<xref rid="B85" ref-type="bibr">Zhou et al., 2021</xref>). The three revealed structures of colibactin are shown in <xref rid="F3" ref-type="fig">Figure 3</xref>.</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>Confirmed structure of colibactin(s).</p></caption><graphic xlink:href="fphar-13-958012-g003" position="float"/></fig></sec></sec><sec id="s3"><title>Colibactin hits unique molecular targets in the eukaryotic cells</title><p>Our gut microbes secrete a plethora of molecules with diverse structures and functions. These molecules can either promote host health such as butyrate or trigger diseases. In addition to colibactin, several microbiome-derived molecules are noted as mediators of diseases, such as the autism-promoting molecule 4-ethylphenylsulfate and the gut genotoxin cyclomodulin (<xref rid="B32" ref-type="bibr">Hsiao et al., 2013</xref>; <xref rid="B14" ref-type="bibr">Buc et al., 2013</xref>). Colibactin might hit other targets in the eukaryotic machinery than what we currently appreciate. A study shows that some synthetic precolibactins exhibited antagonist activity on the mammalian brain receptors such as serotonin 5-hydroxytryptamine type 7 (5-HT7) <italic>in vitro</italic> (<xref rid="B75" ref-type="bibr">Vizcaino et al., 2014</xref>). Of note, 5-HT7 is expressed in dendritic cells. Studies show that 5-HT7 receptor antagonists such as SB-269970 decrease both acute and chronic inflammation in a mouse model of colitis (<xref rid="B36" ref-type="bibr">Kim et al., 2013</xref>). Synthetic precolibactin also showed antagonist activity against dopamine 5 receptors (<xref rid="B75" ref-type="bibr">Vizcaino et al., 2014</xref>). Dopamine receptors are reported to be located in the CNS and gut (Z. S. <xref rid="B41" ref-type="bibr">Li et al., 2006</xref>).</p><sec id="s3-1"><title>Mechanistic insights into colibactin signature mutation</title><p>Colibactin alkylates DNA in the eukaryotic cell leading to colorectal cancer. Overall, colibactin causes an inter-strand DNA cross-link, leading to double-strand breaks in the DNA triggering cell-cycle arrest and further to CRC. The mechanism of colibactin mutation is detailed below and illustrated in <xref rid="F4" ref-type="fig">Figure 4</xref>. DNA double-strand breaks are prevalent in more than half of the patients suffering from inflammatory bowel diseases and CRC (<xref rid="B14" ref-type="bibr">Buc et al., 2013</xref>). The colibactin-DNA signature adduct is detected in both human and animal cells and <italic>in vivo</italic> in experimental animals (<xref rid="B81" ref-type="bibr">Wilson et al., 2019</xref>). A study conducted on mouse models of invasive carcinoma revealed that inoculation with <italic>pks</italic>
<sup>
<italic>+</italic>
</sup>
<italic>E. coli</italic> NC101 increases tumor and enables metastasis (<xref rid="B2" ref-type="bibr">Arthur et al., 2012</xref>). This tumor-promoting activity is diminished with the deletion of the colibactin gene cluster. However, this deletion does not affect the inflammatory status (<xref rid="B2" ref-type="bibr">Arthur et al., 2012</xref>). The DNA alkylation or formation of the covalent bond between the electrophilic warhead of colibactin (azospiro 2,4 bicyclic ring) and the nucleophilic DNA results in the formation of a colibactin&#x02013;DNA adduct and creates a second electrophilic center that further reacts with DNA to form a cross-link. DNA alkylation is mediated by the electrophilic cyclopropane moiety of colibactin. Initially, colibactin forms an unstable adduct, which is considered a biomarker signature for colibactin (<xref rid="B81" ref-type="bibr">Wilson et al., 2019</xref>).</p><fig position="float" id="F4"><label>FIGURE 4</label><caption><p>Illustration of the proposed mechanism of colibactin mutagenesis on the eukaryotic cell. The key structural scaffolds mediating this mechanism is the azospirobicyclic ring (warhead). The process is initiated by a nucleophilic attack on the electrophilic ring, which results in DNA alkylation and creates another electrophilic center subjected to a second alkylation reaction. Two alkylation events cross-link the DNA, which further activate multiple and complex DNA repair mechanisms including Ataxia telangiectasia mutated-and Rad3-related (ATR), Fanconi anemia (FA), homologous recombination (HR) signaling pathways. The DNA double strands break may be the product of the repair system or spontaneously formed. Accumulation of this mutation might initiate colorectal cancer.</p></caption><graphic xlink:href="fphar-13-958012-g004" position="float"/></fig><p>Cross-linked DNA adducts trigger multiple DNA repair signaling pathways, leading to the formation of double-strand breaks and further carcinogenesis (<xref rid="F4" ref-type="fig">Figure 4</xref>). Another research study proposed an alternative mechanism of formation of this characteristic DNA mutation involving cupper-mediated oxidative damage (<xref rid="B42" ref-type="bibr">Li et al., 2019</xref>). DNA alkylating agents constitute a major class of chemotherapeutics that cause cytotoxic DNA damage and collateral mutagenic damage, leading to cell death. This damaging process is defended by several cellular mechanisms, including base excision repair, mismatch repair, and direct DNA damage reversal. The response to alkylating agents required delicate coordination between repair pathways and show much variability between cells and individuals as reviewed (<xref rid="B23" ref-type="bibr">Fu et al., 2012</xref>). Alkylating agents attack the nitrogen or oxygen atoms in the DNA nitrogenous base. Alkylating agents could be monofunctional if they only have one active moiety and can attack a single site on DNA or bifunctional if they have two reactive moieties and can bind to two separate bases and consequently crosslink DNA. In 2016, Healy et al. validated the hypothesis that colibactin alkylates the DNA by cyclopropane ring opening via the formation of unsaturated imines. The authors synthesized 13 structural mimics of colibactin and tested their DNA alkylation potential (<xref rid="B27" ref-type="bibr">Healy et al., 2016a</xref>). In 2019, Wilson et al. used chemical synthesis coupled with an untargeted DNA adductomic approach to reveal DNA alkylation in HeLa cell lines incubated with a colibactin-producing strain of <italic>E. coli</italic> (<xref rid="B81" ref-type="bibr">Wilson et al., 2019</xref>). The same reaction is observed <italic>in vivo</italic> in mice (<xref rid="B81" ref-type="bibr">Wilson et al., 2019</xref>). The authors reveal that this covalent DNA alkylation is mediated by the electrophilic cyclopropane moiety of colibactin (<xref rid="B81" ref-type="bibr">Wilson et al., 2019</xref>). Other data show that colibactin cross-links DNA. The study employed NMR spectroscopy and bioinformatics-guided isotopic labeling to characterize the colibactin warhead (<xref rid="B74" ref-type="bibr">Vizcaino and Crawford 2015</xref>). The synthetic colibactin mimic contains a spiro bicyclic structure and can cross-links duplex DNA <italic>in vitro</italic>. The authors proposed that colibactin alkylates DNA via a homo-Michael addition reaction, turning colibactin into a second Michael receptor. Thereafter, intramolecular Michael addition will generate a DNA cross-link (<xref rid="B74" ref-type="bibr">Vizcaino and Crawford 2015</xref>). This hypothesis is supported by pieces of evidence. First, is the observation that precolibactins do not form much of the higher molecular weight adduct product when reacting with linearized plasmid DNA. Second, synthetic colibactin inspired by the biosynthetic information showed that the cyclopropane ring could be a target for thiol nucleophile attack and is essential to shearing the DNA (<xref rid="B27" ref-type="bibr">Healy et al., 2016a</xref>). Further results based on gel electrophoresis reveal that, upon artificial dimerization, these colibactin mimics cross-link the DNA.</p></sec><sec id="s3-2"><title>Colibactin-induced events leading to inflammation and cancer</title><p>The interplay between genotoxic molecules such as colibactin and inflammation is not clear. It is speculated that DNA damage initiates tumor formation while inflammatory cytokines and cells promote it by creating a microenvironment that enables more DNA damage (<xref rid="B3" ref-type="bibr">Balkwill and Mantovani 2001</xref>; <xref rid="B73" ref-type="bibr">Ullman and Itzkowitz 2011</xref>) by, for example, inducing gene expression of genotoxic molecules. Previous studies show that microbial colonization enhances the development of cancer in mice that are genetically susceptible to inflammation (<xref rid="B73" ref-type="bibr">Ullman and Itzkowitz 2011</xref>). A shift in gut microbes was observed during inflammation, with unknown directionality, characterized by enrichment in genera of <italic>E. coli</italic>, <italic>Akkermansia</italic>, <italic>Shigella</italic>, and <italic>Bacteroides</italic> and a sharp reduction in Lachnospiraceae, Muribaculaceae, and Lactobacilli (<xref rid="B38" ref-type="bibr">Lang et al., 2020</xref>). Another study suggested that the microbial shift is associated with inflammation in the first place and not with cancer in the colitis-susceptible Il10<sup>&#x02212;/&#x02212;</sup> mouse strain. Among the sifted species, <italic>E. coli</italic> showed a 100-fold increase in colitis (<xref rid="B73" ref-type="bibr">Ullman and Itzkowitz 2011</xref>). Additionally, <italic>E. coli</italic> NC101 causes profound colitis in germ-free mice with 80% of the subjects developing adenocarcinoma (<xref rid="B73" ref-type="bibr">Ullman and Itzkowitz 2011</xref>), again questioning the directionality of the association. Another study used <italic>in vitro</italic> 3-D cell culture models to examine the host factors that might contribute to susceptibility to colibactin-induced cancer. The authors reported that the presence of the expression of mucin genes in forming the mucous layer that adheres to the intestinal epithelia decreased the genotoxic effect of colibactin. Moreover, the removal of the mucous layer in other models restored the genotoxicity (<xref rid="B60" ref-type="bibr">Reuter et al., 2018</xref>). Since inflammation is associated with degradation of the mucous layer and a decrease in the tight junction protein, also known as &#x0201c;leaky gut&#x0201d; that might be another factor to add to the colibactin&#x02013;inflammation&#x02013;cancer equation. Inflammation also allows leakage of microbes and other microbial products, not only colibactin, which flares up an even more intense immune response (<xref rid="B1" ref-type="bibr">Ahmad et al., 2017</xref>; <xref rid="B35" ref-type="bibr">Kidane et al., 2014</xref>). Of note is that the microbial composition in the presence of colibactin is altered, which might promote the abundance of pro-inflammatory bacteria. The interplay between colibactin-induced inflammation and cancer is illustrated in <xref rid="F5" ref-type="fig">Figure 5</xref>.</p><fig position="float" id="F5"><label>FIGURE 5</label><caption><p>Colibactin hits targets in both eukaryotic and prokaryotic cells. Illustrations show an overall mechanism by which colibactin mediates host&#x02013;microbe interaction. Colibactin shapes the gut microbial community by selective killing of some species through induction of prophages and/or stimulation of the virulence factor expression. Meanwhile, colibactin induces double strand breaks in host DNA. The altered microbial community together with the genetic abnormalities caused by colibactin triggers an inflammatory microenvironment, which might induce synthesis of more colibactin, leading to even greater damage that might result in CRC.</p></caption><graphic xlink:href="fphar-13-958012-g005" position="float"/></fig></sec></sec><sec id="s4"><title>Colibactin hits targets of the prokaryotic cells controlling microbiome structure</title><sec id="s4-1"><title>The genomic organization of the colibactin cluster suggests a potential antimicrobial activity</title><p>Microbes are known to produce microbial toxins such as antibiotics to kill competing microbes and gain significant ecological competency. To protect themselves, the toxin-producing strains mostly harbor self-resistance genes. The presence of a self-resistance gene in the colibactin cluster suggests that colibactin is not only affecting cellular target in the human cell but also the bacterial cell. The biosynthetic gene cluster of colibactin ends with a resistance gene encoding a 170-amino acid protein named <italic>clbS. clbS</italic> encodes a cyclopropane hydrolase, resulting in the ring-opening of the DNA alkylating scaffolds, conferring self-resistance to producing strains (<xref rid="B71" ref-type="bibr">Tripathi et al., 2017</xref>) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). This gene is not only present in colibactin-producing strains but also in some other strains that lack the entire colibactin cluster, suggesting that this gene is transferable within the bacterial community by horizontal gene transfer to gain an ecological advantage. <italic>clbS</italic>-like genes with at least 50% sequence similarity have been found in members of the human gut microbiome, namely, <italic>Escherichia albertii</italic>, <italic>Kluyvera intestini</italic>, and <italic>Metakosakonia</italic> sp. and the honeybee microbiome, namely, <italic>Snodgrasella alvi</italic> (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>). Heterologous expression of these four clbS-like genes resulted in attenuated DNA damage and phage lysis when co-cultured with a colibactin-producing strain, suggesting that acquisition of clbS provides immunity against colibactin-induceddamage. Interestingly, <italic>clbS</italic> protects against colibactin-specific induction of prophages but provides no protection against other inducing agents such as MMC. This resistance is intra-cellular and is not shared between cells (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>). Other studies show that deletion of the <italic>clbS</italic> gene does not kill the strain but its growth will be dependent on the DNA repair mechanism (<xref rid="B10" ref-type="bibr">Bossuet-Greif et al., 2016</xref>).</p></sec><sec id="s4-2"><title>Molecular targets behind colibactin activity on prokaryotes</title><p>Colibactin belongs to the PKS/NRPS natural products, which include many antibiotics such as daptomycin and &#x003b2;-lactams (<xref rid="B77" ref-type="bibr">Walsh 2004</xref>). Earlier studies suggested that colibactin might have antibiotic-like activity but the precise mechanism was not clear. A study showed that <italic>E. coli</italic> harboring a colibactin cluster exhibits growth inhibition against multi-resistant <italic>Staphylococcus aureus</italic> in the agar diffusion method and growth competition assay. This activity is observed in 95% of the tested strains, while the &#x00394;clbP <italic>E. coli</italic> lost this activity (T. <xref rid="B21" ref-type="bibr">Fa&#x000ef;s et al., 2016</xref>). The authors reported that this activity requires live culture, suggesting it is an inducible trait. Another study reported that inoculation of pregnant mice with a colibactin harboring strain resulted in a decreased abundance of firmicutes and a significant alteration in microbial diversity in pups, especially after 35 days of birth (<xref rid="B72" ref-type="bibr">Tronnet et al., 2020</xref>). Interestingly, the authors reported increased activity in DNA repair pathways, suggesting that colibactin not only modulates the structure of gut microbes but also their function (<xref rid="B72" ref-type="bibr">Tronnet et al., 2020</xref>). Another research study shows that the colibactin biosynthetic gene (<italic>clbA</italic>) might affect siderophore biosynthesis enhancing its producer fitness (<xref rid="B50" ref-type="bibr">Martin et al., 2013</xref>).</p><p>In 2022, the Balskus group revealed an interesting mechanism beyond the observed activities of colibactin in shaping the microbial population (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>). They discovered that colibactin-induced damage activates SOS signaling pathways, leading to the induction of prophages exerting lethal action on their host bacteria. The authors show that the effect of colibactin on prophages extends to a wide range of phages residing in phylogenetically distinct bacteria, including <italic>Salmonella typhimurium</italic>, <italic>Staphylococcus aureus</italic>, <italic>Citrobacter</italic> rodentium, and <italic>Enterococcus</italic> faecium (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>). Interestingly, there is a significant increase in Shiga toxin production upon co-culture of <italic>C. rodentium</italic> (harboring Stx genes) with <italic>pks</italic> + <italic>E. coli</italic> (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>)<italic>.</italic> Induction of prophages enables selective lethal action against other members of the microbial community, providing an elegant ecological advantage and enhancing the competitiveness of the producing strain.</p></sec><sec id="s4-3"><title>Molecular mechanism of prophage induction following DNA damage in the host</title><p>Lytic activation of prophages in bacterial lysogens is normally induced by DNA damage, such as after exposure to UV radiation or DNA damaging agents such as mitomycin C (MMC) (<xref rid="B39" ref-type="bibr">Lee et al., 2006</xref>; <xref rid="B33" ref-type="bibr">Humphrey, Stanton, and Jensen 1995</xref>). In addition to DNA damage, other internal and external stimuli might lead to prophage induction, such as pH, heat, reactive oxygen species (ROS), or even spontaneous induction (<xref rid="B54" ref-type="bibr">Nanda, Thormann, and Frunzke 2015</xref>). Maintenance of lysogeny is tightly controlled by the activity of the &#x003bb; CI repressor proteins. Two dimers of CI bind to the operator regions of phage genes and suppress their expression (<xref rid="B31" ref-type="bibr">Hochschild 2002</xref>; <xref rid="B45" ref-type="bibr">Little, Shepley, and Wert 1999</xref>). The CI protein is a molecular switch that controls lysogeny in lambda phages. CI binds to operator regions of phage genes and represses their expression while inducing its own expression. DNA damage activates the master regulator RecA, resulting in de-repression of SOS genes mediated by cleavage of their transcriptional repressor LexA (<xref rid="B26" ref-type="bibr">Gimble and Sauer 1989</xref>; <xref rid="B46" ref-type="bibr">Little and Michalowski 2010</xref>; <xref rid="B69" ref-type="bibr">Thomason et al., 2021</xref>). Activation of SOS genes and RecA leads to the cleavage of the CI protein resulting in the de-repression of phage genes to enter the lytic cycle (<xref rid="B31" ref-type="bibr">Hochschild 2002</xref>; <xref rid="B45" ref-type="bibr">Little, Shepley, and Wert 1999</xref>). This molecular mechanism is simply illustrated in <xref rid="F6" ref-type="fig">Figure 6</xref>. Genetic mutations affecting dimerization of lambda repressor increase the rate of its cleavage, while repressor dimer stabilized by covalent disulfide bond resists cleavage (<xref rid="B26" ref-type="bibr">Gimble and Sauer 1989</xref>). An exception is the prophages in <italic>Salmonella</italic> genomes, which uses another inductive strategy based on the use of anti-repressor molecules that bind the dimer without cleavage, leading to its dissociation from the DNA. Production of these anti-repressors is under the direct control of LexA (<xref rid="B40" ref-type="bibr">Lemire, Figueroa-Bossi, and Bossi 2011</xref>).</p><fig position="float" id="F6"><label>FIGURE 6</label><caption><p>Illustration of prophage activation following DNA damage inside a bacterial cell. DNA damage induces cleavage of phage repressor genes mediated by SOS signaling. Cleavage of the phage repressor leads to exciton of prophage from the bacterial chromosome, synthesis of phage-related genes and proteins, assembly, cell lysis, and phage release. This illustration is simplified to communicate the main idea; for example CI binds to two distant regions and not only to one site as shown for simplicity of the illustration.</p></caption><graphic xlink:href="fphar-13-958012-g006" position="float"/></fig></sec><sec id="s4-4"><title>Prophages contribute to the ecological fitness of harboring strains</title><p>Viral genes make up to 20% of microbial genomes, either as prophage-like elements, phage remnants, or fully prophages that could be induced into the lytic life cycle (<xref rid="B78" ref-type="bibr">Wang et al., 2010</xref>). These prophages contribute to the ecological fitness and virulence of the lysogens. Reports show that lysogens can use prophages as a survival strategy (<xref rid="B9" ref-type="bibr">Bossi et al., 2003</xref>; <xref rid="B24" ref-type="bibr">Gama et al., 2013</xref>). For example, in a mixed culture, <italic>Salmonella enterica</italic> induces its prophages, leading to the killing of some self-cells while the others are converted back to lysogens. The released prophages are then used as a weapon to kill competitors although it results in some self-destruction. This strategy will also benefit the phage by spreading its genes (<xref rid="B9" ref-type="bibr">Bossi et al., 2003</xref>; <xref rid="B24" ref-type="bibr">Gama et al., 2013</xref>). Another example is the induction of prophages in <italic>Streptococcus pneumoniae</italic> to wipe off <italic>S. aureus</italic> via the production of hydrogen peroxide-inducing SOS genes. Induction of SOS leads to activation of prophages in <italic>S. aureus</italic>, which are mostly lysogens while S. <italic>pneumoniae</italic> are immune, giving S. <italic>pneumoniae</italic> an ecological advantage to dominate (<xref rid="B64" ref-type="bibr">Selva et al., 2009</xref>; <xref rid="B58" ref-type="bibr">Pericone et al., 2003</xref>). A study shows that deletion of nine cryptic prophages from <italic>E-coli</italic> suppresses fitness by rendering the bacteria more susceptible to sublethal concentrations of &#x003b2;-lactam and quinolone antibiotics. Moreover, this deletion rendered the bacteria less able to form biofilms and more prone to damage caused by acid or osmotic pressure (<xref rid="B78" ref-type="bibr">Wang et al., 2010</xref>). A study shows that prophages enable biofilm formation in <italic>Pseudomonas aeruginosa</italic>, contributing to its virulence and. when cells die in the biofilm, the prophage is converted to a super infective form (<xref rid="B61" ref-type="bibr">Rice et al., 2009</xref>). Biofilm is a group behavior in which bacterial cells adhere to one another and solid surfaces using a sticky matrix made of extracellular proteins, carbohydrates, and DNA molecules (<xref rid="B48" ref-type="bibr">Madsen et al., 2012</xref>). The formation of biofilm is a virulence strategy that helps enable bacteria to resist antibiotics and host immune defense. Prophage induction in a biofilm will lead to the accumulation of extracellular DNA promoting horizontal gene transfer and enhancing diversification of the microbial community within the biofilm (<xref rid="B52" ref-type="bibr">Molin and Tolker-Nielsen 2003</xref>). The role of prophages on biofilm formation and further consequences on host fitness is reviewed (<xref rid="B54" ref-type="bibr">Nanda, Thormann, and Frunzke 2015</xref>). The production of toxins is a crucial virulence trait for pathogens (<xref rid="B13" ref-type="bibr">Brown et al., 2006</xref>). Some toxins are encoded by bacteriophages, including cholera toxin (Ctx) and Shiga toxins (Stx), required for the virulence of <italic>Vibrio cholerae</italic> and <italic>E. coli</italic>, respectively (<xref rid="B76" ref-type="bibr">Waldor and Mekalanos 1996</xref>; <xref rid="B55" ref-type="bibr">Neely and Friedman 1998</xref>). For example, Shiga toxin (Stx) in enterohemorragic <italic>E. coli</italic> enables bacterial cells to attach and colonize the gut epithelia (<xref rid="B62" ref-type="bibr">Robinson et al., 2006</xref>). Similarly, some cells of <italic>E. faecalis</italic> V583 and <italic>Streptococcus mitis</italic> induce prophages to express phage genes to help the remaining cells adhere to human platelets, leading to systemic infection (<xref rid="B51" ref-type="bibr">Matos et al., 2013</xref>; <xref rid="B65" ref-type="bibr">Seo et al., 2010</xref>). This regulatory activity of microbiome-secreted molecules has been noted before. For example, quinolone antibiotics increase the production of Stx toxin via activation of prophages via SOS response (<xref rid="B59" ref-type="bibr">Pleguezuelos-Manzano et al., 2020</xref>). Co-culture of colibactin with <italic>Citrobacter rodentium</italic> increases the production of Stx (<xref rid="B67" ref-type="bibr">Silpe et al., 2022</xref>). Another interesting activity of colibactin was reported by <xref rid="B49" ref-type="bibr">Marcq et al. (2014)</xref>. Driven by the association between pks<sup>+</sup>
<italic>E. coli</italic> strains and septicemia, the authors investigated the effect of colibactin-harboring strains on lymphopenia and sepsis. The results show that colibactin-producing <italic>E. coli</italic> causes the characteristic double-strand break in the DNA of lymphocytes, leading to an exaggerated lymphopenia and subsequent low survival rate from bacteremia in mice (<xref rid="B49" ref-type="bibr">Marcq et al., 2014</xref>).</p></sec></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p>Colibactin demonstrates the potential of microbiome secreted chemistry to hit multiple targets spanning prokaryotic and eukaryotic cell machinery. It is interesting to speculate that colibactin gives the producing species an ecological advantage in occupying specific niches such as the human gut by controlling other competitive microbes. Understanding how precisely colibactin-producing strains alter gut microbiome composition and their further indirect impact on human health and diseases seems exciting. Of note, we still do not appreciate all the microbiome species that we host in our bodies or their cryptic genes and encoded chemistry. Revealing the microbiome products that exert microbial control and affect population dynamics will help to advance better strategies to tackle the antibiotic resistance crisis. Microbiome chemistry is certainly a new uncharted Frontier for understanding mediators of human conditions and developing innovative therapeutics or diagnostic biomarkers. For example, delivering colibactin mimics or genes to induce the lethal killing of a cancer cell or as an antimicrobial for life-threatening biofilm infection.</p><sec id="s5-1"><title>Is colibactin a harmful molecule?</title><p>Host-associated microbes produce molecules that help to increase their ecological fitness and competitiveness and to establish a long-term, mostly symbiotic, relationship with the host. From an ecological perspective, we can imagine colibactin as a beneficial microbial product that is produced to shape the microbial community and confer beneficial traits to the host, such as decreasing inflammation as long as the mutualistic relationship is established. Evidence for this hypothesis came from the research on Nissle 1917. The efficacy of probiotic <italic>E-coli</italic> Nissle 1917 in treating colitis and preventing further remission is even comparable to that of mesalazine, the gold standard drug in the treatment of colitis (<xref rid="B37" ref-type="bibr">Kruis et al., 2004</xref>). The mechanism of action involves modulation of cytokine expression. Interestingly, further investigation on Nissle 1917 activity suggests that its beneficial anti-inflammatory activity is dependent on the expression of the colibactin biosynthetic pathway (<xref rid="B57" ref-type="bibr">Olier et al., 2012</xref>). Knockout strains that lost the ability to express the colibactin cluster not only lost the anti-inflammatory activity but also resulted in more inflammation (<xref rid="B57" ref-type="bibr">Olier et al., 2012</xref>). Moreover, inflammation is thought to be a triggering signal for further expression of the colibactin gene cluster. Chronic inflammation and accumulation of DNA damage will eventually lead to cancer development. The question now is, do these microbiome strains, or more specifically colibactin, initiate cancer or evolved to combat cancer and act as an immunomodulin based on the activity profile of <italic>E. coli</italic> Nissle 1917? One can postulate that it produces colibactin to kill transformative cells at the beginning of inflammation in a similar way to chemotherapeutic agents and more inflammation triggers more synthesis of the mysterious molecule(s). This bidirectional dependency is puzzling and poses an outstanding question on the directionality of microbiome diseases association and warns of the urgent need for a holistic deep understanding of the microbiome secreted chemistry evolved to hit multiple cellular targets under very tight and complex regulation resulting in a variety of negative and positive outcomes for the host. Another interesting hypothesis is that the colibactin biosynthetic cluster encodes or supplies precursor molecules with immunomodulatory activity as originally proposed (<xref rid="B57" ref-type="bibr">Olier et al., 2012</xref>). Support for this hypothesis comes from the strong association between colitis and microbial dysbiosis, so it is interesting to speculate on the role of colibactin in shaping microbiome structure and whether it may restore the balanced composition to the pre-colitis status. However, the members of Enterobacteriacea are often considered proinflammatory, and some reports show significant enrichment in Enterobacteriacea with the onset of gastrointestinal inflammatory conditions (<xref rid="B25" ref-type="bibr">Garrett et al., 2010</xref>) and the dominant presence of adherent-invasive strains of <italic>E. coli</italic> such as LF82 (<xref rid="B15" ref-type="bibr">Carvalho et al., 2008</xref>), belonging to the same phylogenetic group as Nissle 1917, although it lacks the colibactin genomic cluster. Taken together, our knowledge of microbiome mediators and their evolved function is still in its infancy. Despite the explosion of research on the microbiome, the diversity and richness in species of the microbiome, their cryptic genes, and secreted molecules are still a dark matter.</p></sec><sec id="s5-2"><title>A proposed model for colibactin&#x02013;microbe&#x02013;host interaction and health outcome</title><p>Host-associated microbes produce toxic molecules with the primary function of killing competitors and gaining an ecological advantage to dominate a particular niche. However, these toxins might also hit molecular targets in the host. Considering that the priority function of colibactin is microbial related, we can propose that the reasonable order of events leading to CRC might be as follows: 1) colibactin shapes microbial composition in the gut to modulate inflammation, especially during microbial dysbiosis; 2) chronic dysbiosis triggers inflammation, which leads to leaky gut; 3) colibactin diffuses inside the eukaryotic cell and causes DNA damage eliciting the repair mechanism; 4) chronic inflammatory microenvironment further advances the microbial dysbiosis, and gut permeability resulted in more diffusion of colibactin to eukaryotic cells (or maybe an induction of its synthesis); and 5) under high load of colibactin, accumulation of DNA damage might occur leading to colorectal cancer (<xref rid="F7" ref-type="fig">Figure 7</xref>). This situation gets worse with a genetic predisposition to inflammation or defect in the DNA repair pathways. Considering this model, chronic microbial dysbiosis and inflammation are crucial for colibactin-induced colorectal cancer and might serve as a risk factor to predicting CRC, especially if this is combined with genetic disorders in genes related to the DNA repair pathways or immune function. This understanding is not only helpful in predicting risks but also in taking preventative measures such as implementing an anti-inflammatory diet for high-risk groups to decrease the incidence of CRC.</p><fig position="float" id="F7"><label>FIGURE 7</label><caption><p>Proposed mechanistic model for the sequence of the events of colibactin-induced cancer. <bold>(A)</bold> Colibactin induces dysbiosis, <bold>(B)</bold> dysbiosis results in inflammation and leaky gut, <bold>(C)</bold> colibactin diffuses inside the cell resulting in DNA damage, <bold>(D)</bold> chronic inflammation increases the load of colibactin inside the cell and more DNA damage, and <bold>(E)</bold> accumulating DNA damage leads to CRC.</p></caption><graphic xlink:href="fphar-13-958012-g007" position="float"/></fig></sec></sec></body><back><sec id="s6"><title>Author contributions</title><p>The author confirms being the sole contributor of this work and has approved it for publication.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>R.</given-names></name><name><surname>Sorrell</surname><given-names>M. F.</given-names></name><name><surname>Batra</surname><given-names>S. K.</given-names></name><name><surname>Dhawan</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>A. B.</given-names></name><name><surname>Dhawan</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Gut permeability and mucosal inflammation: Bad, good or context dependent</article-title>. <source>Mucosal Immunol.</source>
<volume>10</volume> (<issue>2</issue>), <fpage>307</fpage>&#x02013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1038/mi.2016.128</pub-id>
<pub-id pub-id-type="pmid">28120842</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arthur</surname><given-names>Janelle C.</given-names></name><name><surname>Perez-Chanona</surname><given-names>Ernesto</given-names></name><name><surname>M&#x000fc;hlbauer</surname><given-names>Marcus</given-names></name><name><surname>Tomkovich</surname><given-names>Sarah</given-names></name><name><surname>Uronis</surname><given-names>Joshua M.</given-names></name><name><surname>Fan</surname><given-names>Ting-Jia</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Intestinal inflammation targets cancer-inducing activity of the microbiota</article-title>. <source>Science</source>
<volume>338</volume> (<issue>6103</issue>), <fpage>120</fpage>&#x02013;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1126/science.1224820</pub-id>
<pub-id pub-id-type="pmid">22903521</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F.</given-names></name><name><surname>Mantovani</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Inflammation and cancer: Back to virchow?</article-title>
<source>Lancet (London, Engl.</source>
<volume>357</volume> (<issue>9255</issue>), <fpage>539</fpage>&#x02013;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balskus</surname><given-names>Emily P.</given-names></name></person-group> (<year>2015</year>). <article-title>Colibactin: Understanding an elusive gut bacterial genotoxin</article-title>. <source>Nat. Prod. Rep.</source>
<volume>32</volume> (<issue>11</issue>), <fpage>1534</fpage>&#x02013;<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1039/c5np00091b</pub-id>
<pub-id pub-id-type="pmid">26390983</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bian</surname><given-names>Xiaoying</given-names></name><name><surname>Fu</surname><given-names>Jun</given-names></name><name><surname>Plaza</surname><given-names>Alberto</given-names></name><name><surname>Herrmann</surname><given-names>Jennifer</given-names></name><name><surname>Pistorius</surname><given-names>Dominik</given-names></name><name><surname>Zhang</surname><given-names>Youming</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>
<italic>In vivo</italic> evidence for a prodrug activation mechanism during colibactin maturation</article-title>. <source>Chembiochem</source>
<volume>14</volume> (<issue>10</issue>), <fpage>1194</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201300208</pub-id>
<pub-id pub-id-type="pmid">23744512</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bian</surname><given-names>Xiaoying</given-names></name><name><surname>Plaza</surname><given-names>Alberto</given-names></name><name><surname>Zhang</surname><given-names>Youming</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>Rolf</given-names></name></person-group> (<year>2015</year>). <article-title>Two more pieces of the colibactin genotoxin puzzle from Escherichia coli show incorporation of an unusual 1-aminocyclopropanecarboxylic acid moiety</article-title>. <source>Chem. Sci.</source>
<volume>6</volume> (<issue>5</issue>), <fpage>3154</fpage>&#x02013;<lpage>3160</lpage>. <pub-id pub-id-type="doi">10.1039/C5SC00101C</pub-id>
<pub-id pub-id-type="pmid">28706687</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bode</surname><given-names>Helge B.</given-names></name></person-group> (<year>2015</year>). <article-title>The microbes inside us and the race for colibactin</article-title>. <source>Angew. Chem. Int. Ed. Engl.</source>
<volume>54</volume> (<issue>36</issue>), <fpage>10408</fpage>&#x02013;<lpage>10411</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201505341</pub-id>
<pub-id pub-id-type="pmid">26184782</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bondarev</surname><given-names>Vladimir</given-names></name><name><surname>Richter</surname><given-names>Michael</given-names></name><name><surname>Romano</surname><given-names>Stefano</given-names></name><name><surname>Piel</surname><given-names>J&#x000f6;rn</given-names></name><name><surname>Schwedt</surname><given-names>Anne</given-names></name><name><surname>Schulz-Vogt</surname><given-names>Heide N.</given-names></name></person-group> (<year>2013</year>). <article-title>The genus Pseudovibrio contains metabolically versatile bacteria adapted for symbiosis</article-title>. <source>Environ. Microbiol.</source>
<volume>15</volume> (<issue>7</issue>), <fpage>2095</fpage>&#x02013;<lpage>2113</lpage>. <pub-id pub-id-type="doi">10.1111/1462-2920.12123</pub-id>
<pub-id pub-id-type="pmid">23601235</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bossi</surname><given-names>Lionello</given-names></name><name><surname>Fuentes</surname><given-names>Juan A.</given-names></name><name><surname>Guido</surname><given-names>Mora</given-names></name><name><surname>Figueroa-Bossi</surname><given-names>Nara</given-names></name></person-group> (<year>2003</year>). <article-title>Prophage contribution to bacterial population dynamics</article-title>. <source>J. Bacteriol.</source>
<volume>185</volume> (<issue>21</issue>), <fpage>6467</fpage>&#x02013;<lpage>6471</lpage>. <pub-id pub-id-type="doi">10.1128/jb.185.21.6467-6471.2003</pub-id>
<pub-id pub-id-type="pmid">14563883</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bossuet-Greif</surname><given-names>Nad&#x000e8;ge</given-names></name><name><surname>Dubois</surname><given-names>Damien</given-names></name><name><surname>Petit</surname><given-names>Claude</given-names></name><name><surname>Tronnet</surname><given-names>Sophie</given-names></name><name><surname>Martin</surname><given-names>Patricia</given-names></name><name><surname>Bonnet</surname><given-names>Richard</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Escherichia coli ClbS is a colibactin resistance protein</article-title>. <source>Mol. Microbiol.</source>
<volume>99</volume> (<issue>5</issue>), <fpage>897</fpage>&#x02013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.13272</pub-id>
<pub-id pub-id-type="pmid">26560421</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brotherton</surname><given-names>Carolyn A.</given-names></name><name><surname>Balskus</surname><given-names>Emily P.</given-names></name></person-group> (<year>2013</year>). <article-title>A prodrug resistance mechanism is involved in colibactin biosynthesis and cytotoxicity</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>135</volume> (<issue>9</issue>), <fpage>3359</fpage>&#x02013;<lpage>3362</lpage>. <pub-id pub-id-type="doi">10.1021/ja312154m</pub-id>
<pub-id pub-id-type="pmid">23406518</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brotherton</surname><given-names>Carolyn A.</given-names></name><name><surname>Wilson</surname><given-names>Matthew</given-names></name><name><surname>Byrd</surname><given-names>Gary</given-names></name><name><surname>Balskus</surname><given-names>Emily P.</given-names></name></person-group> (<year>2015</year>). <article-title>Isolation of a metabolite from the pks island provides insights into colibactin biosynthesis and activity</article-title>. <source>Org. Lett.</source>
<volume>17</volume> (<issue>6</issue>), <fpage>1545</fpage>&#x02013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.5b00432</pub-id>
<pub-id pub-id-type="pmid">25753745</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>Nat F.</given-names></name><name><surname>Wickham</surname><given-names>Mark E.</given-names></name><name><surname>Coombes</surname><given-names>Brian K.</given-names></name><name><surname>Finlay</surname><given-names>B. Brett</given-names></name></person-group> (<year>2006</year>). <article-title>Crossing the line: Selection and evolution of virulence traits</article-title>. <source>PLoS Pathog.</source>
<volume>2</volume> (<issue>5</issue>), <fpage>e42</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0020042</pub-id>
<pub-id pub-id-type="pmid">16733541</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buc</surname><given-names>Emmanuel</given-names></name><name><surname>Dubois</surname><given-names>Damien</given-names></name><name><surname>Sauvanet</surname><given-names>Pierre</given-names></name><name><surname>Raisch</surname><given-names>Jennifer</given-names></name><name><surname>Delmas</surname><given-names>Julien</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>Arlette</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>High prevalence of mucosa-associated E. Coli producing cyclomodulin and genotoxin in colon cancer</article-title>. <source>PloS One</source>
<volume>8</volume> (<issue>2</issue>), <fpage>e56964</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0056964</pub-id>
<pub-id pub-id-type="pmid">23457644</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>Fr&#x000e9;d&#x000e9;ric A.</given-names></name><name><surname>Barnich</surname><given-names>Nicolas</given-names></name><name><surname>Sauvanet</surname><given-names>Pierre</given-names></name><name><surname>Darcha</surname><given-names>Claude</given-names></name><name><surname>Gelot</surname><given-names>Agathe</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>Arlette</given-names></name></person-group> (<year>2008</year>). <article-title>Crohn&#x02019;s disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin</article-title>. <source>Inflamm. Bowel Dis.</source>
<volume>14</volume> (<issue>8</issue>), <fpage>1051</fpage>&#x02013;<lpage>1060</lpage>. <pub-id pub-id-type="doi">10.1002/ibd.20423</pub-id>
<pub-id pub-id-type="pmid">18338780</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cougnoux</surname><given-names>Antony</given-names></name><name><surname>Gibold</surname><given-names>Lucie</given-names></name><name><surname>Robin</surname><given-names>Frederic</given-names></name><name><surname>Dubois</surname><given-names>Damien</given-names></name><name><surname>Pradel</surname><given-names>Nathalie</given-names></name><name><surname>Darfeuille-Michaud</surname><given-names>Arlette</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP</article-title>. <source>J. Mol. Biol.</source>
<volume>424</volume> (<issue>3&#x02013;4</issue>), <fpage>203</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2012.09.017</pub-id>
<pub-id pub-id-type="pmid">23041299</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vos</surname><given-names>Willem M.</given-names></name><name><surname>Herbert</surname><given-names>Tilg</given-names></name><name><surname>Van Hul</surname><given-names>Matthias</given-names></name><name><surname>Cani</surname><given-names>Patrice D.</given-names></name></person-group> (<year>2022</year>). <article-title>Gut microbiome and health: Mechanistic insights</article-title>. <source>Gut</source>
<volume>71</volume> (<issue>5</issue>), <fpage>1020</fpage>&#x02013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2021-326789</pub-id>
<pub-id pub-id-type="pmid">35105664</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dhanaraju</surname><given-names>Rajkumar</given-names></name><name><surname>Rao</surname><given-names>Desirazu N.</given-names></name></person-group> (<year>2022</year>). <article-title>The human microbiome: An acquired organ?</article-title>
<source>Reson.</source>
<volume>27</volume> (<issue>2</issue>), <fpage>247</fpage>&#x02013;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1007/s12045-022-1312-7</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubois</surname><given-names>Damien</given-names></name><name><surname>Baron</surname><given-names>Olivier</given-names></name><name><surname>Antony</surname><given-names>Cougnoux</given-names></name><name><surname>Delmas</surname><given-names>Julien</given-names></name><name><surname>Pradel</surname><given-names>Nathalie</given-names></name><name><surname>Boury</surname><given-names>Mich&#x000e8;le</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>ClbP is a prototype of a peptidase subgroup involved in biosynthesis of nonribosomal peptides</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume> (<issue>41</issue>), <fpage>35562</fpage>&#x02013;<lpage>35570</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.221960</pub-id>
<pub-id pub-id-type="pmid">21795676</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engel</surname><given-names>Philipp</given-names></name><name><surname>Vizcaino</surname><given-names>Maria I.</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name></person-group> (<year>2015</year>). <article-title>Gut symbionts from distinct hosts exhibit genotoxic activity via divergent colibactin biosynthesis pathways</article-title>. <source>Appl. Environ. Microbiol.</source>
<volume>81</volume> (<issue>4</issue>), <fpage>1502</fpage>&#x02013;<lpage>1512</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.03283-14</pub-id>
<pub-id pub-id-type="pmid">25527542</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fa&#x000ef;s</surname><given-names>T.</given-names></name><name><surname>Cougnoux</surname><given-names>A.</given-names></name><name><surname>Dalmasso</surname><given-names>G.</given-names></name><name><surname>Laurent</surname><given-names>F.</given-names></name><name><surname>Delmas</surname><given-names>J.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Antibiotic activity of Escherichia coli against multiresistant Staphylococcus aureus</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>60</volume> (<issue>11</issue>), <fpage>6986</fpage>&#x02013;<lpage>6988</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00130-16</pub-id>
<pub-id pub-id-type="pmid">27600034</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fa&#x000ef;s</surname><given-names>Tiphanie</given-names></name><name><surname>Delmas</surname><given-names>Julien</given-names></name><name><surname>Barnich</surname><given-names>Nicolas</given-names></name><name><surname>Bonnet</surname><given-names>Richard</given-names></name><name><surname>Dalmasso</surname><given-names>Guillaume</given-names></name></person-group> (<year>2018</year>). <article-title>Colibactin: More than a new bacterial toxin</article-title>. <source>Toxins</source>
<volume>10</volume> (<issue>4</issue>), <fpage>E151</fpage>. <pub-id pub-id-type="doi">10.3390/toxins10040151</pub-id>
<pub-id pub-id-type="pmid">29642622</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Dragony</given-names></name><name><surname>Calvo</surname><given-names>Jennifer A.</given-names></name><name><surname>Samson</surname><given-names>Leona D.</given-names></name></person-group> (<year>2012</year>). <article-title>Balancing repair and tolerance of DNA damage caused by alkylating agents</article-title>. <source>Nat. Rev. Cancer</source>
<volume>12</volume> (<issue>2</issue>), <fpage>104</fpage>&#x02013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3185</pub-id>
<pub-id pub-id-type="pmid">22237395</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gama</surname><given-names>Jo&#x000e3;o Alves</given-names></name><name><surname>Reis</surname><given-names>Ana Maria</given-names></name><name><surname>Domingues</surname><given-names>Iolanda</given-names></name><name><surname>Mendes-Soares</surname><given-names>Helena</given-names></name><name><surname>Matos</surname><given-names>Ana Margarida</given-names></name><name><surname>Dionisio</surname><given-names>Francisco</given-names></name></person-group> (<year>2013</year>). <article-title>Temperate bacterial viruses as double-edged swords in bacterial warfare</article-title>. <source>PloS One</source>
<volume>8</volume> (<issue>3</issue>), <fpage>e59043</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0059043</pub-id>
<pub-id pub-id-type="pmid">23536852</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garrett</surname><given-names>Wendy S.</given-names></name><name><surname>Gallini</surname><given-names>Carey A.</given-names></name><name><surname>Yatsunenko</surname><given-names>Tanya</given-names></name><name><surname>Michaud</surname><given-names>Monia</given-names></name><name><surname>DuBois</surname><given-names>Andrea</given-names></name><name><surname>Delaney</surname><given-names>Mary L.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis</article-title>. <source>Cell Host Microbe</source>
<volume>8</volume> (<issue>3</issue>), <fpage>292</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2010.08.004</pub-id>
<pub-id pub-id-type="pmid">20833380</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gimble</surname><given-names>F. S.</given-names></name><name><surname>Sauer</surname><given-names>R. T.</given-names></name></person-group> (<year>1989</year>). <article-title>Lambda repressor mutants that are better substrates for RecA-mediated cleavage</article-title>. <source>J. Mol. Biol.</source>
<volume>206</volume> (<issue>1</issue>), <fpage>29</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(89)90521-4</pub-id>
<pub-id pub-id-type="pmid">2522996</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Healy</surname><given-names>Alan R.</given-names></name><name><surname>Herman</surname><given-names>Nikolayevskiy</given-names></name><name><surname>Patel</surname><given-names>Jaymin R.</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name></person-group> (<year>2016a</year>). <article-title>A mechanistic model for colibactin-induced genotoxicity</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>138</volume> (<issue>48</issue>), <fpage>15563</fpage>&#x02013;<lpage>15570</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.6b10354</pub-id>
<pub-id pub-id-type="pmid">27934011</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Healy</surname><given-names>Alan R.</given-names></name><name><surname>Vizcaino</surname><given-names>Maria I.</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name></person-group> (<year>2016b</year>). <article-title>Convergent and modular synthesis of candidate precolibactins. Structural revision of precolibactin A</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>138</volume> (<issue>16</issue>), <fpage>5426</fpage>&#x02013;<lpage>5432</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.6b02276</pub-id>
<pub-id pub-id-type="pmid">27025153</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Healy</surname><given-names>Alan R.</given-names></name><name><surname>Wernke</surname><given-names>Kevin M.</given-names></name><name><surname>Kim</surname><given-names>Chung Sub</given-names></name><name><surname>Lees</surname><given-names>Nicholas R.</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name></person-group> (<year>2019</year>). <article-title>Synthesis and reactivity of precolibactin 886</article-title>. <source>Nat. Chem.</source>
<volume>11</volume> (<issue>10</issue>), <fpage>890</fpage>&#x02013;<lpage>898</lpage>. <pub-id pub-id-type="doi">10.1038/s41557-019-0338-2</pub-id>
<pub-id pub-id-type="pmid">31548676</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>Yuichiro</given-names></name><name><surname>Tsunematsu</surname><given-names>Yuta</given-names></name><name><surname>Yoshikawa</surname><given-names>Yuko</given-names></name><name><surname>Tamafune</surname><given-names>Ryota</given-names></name><name><surname>Matsuzaki</surname><given-names>Nobuo</given-names></name><name><surname>Iwashita</surname><given-names>Yuji</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Activity-based probe for screening of high-colibactin producers from clinical samples</article-title>. <source>Org. Lett.</source>
<volume>21</volume> (<issue>12</issue>), <fpage>4490</fpage>&#x02013;<lpage>4494</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.9b01345</pub-id>
<pub-id pub-id-type="pmid">31192617</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hochschild</surname><given-names>Ann.</given-names></name></person-group> (<year>2002</year>). <article-title>The &#x003bb; switch: CI closes the gap in autoregulation</article-title>. <source>Curr. Biol.</source>
<volume>12</volume> (<issue>3</issue>), <fpage>R87</fpage>&#x02013;<lpage>R89</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-9822(02)00667-X</pub-id>
<pub-id pub-id-type="pmid">11839286</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>Elaine Y.</given-names></name><name><surname>McBride</surname><given-names>Sara W.</given-names></name><name><surname>Hsien</surname><given-names>Sophia</given-names></name><name><surname>Gil</surname><given-names>Sharon</given-names></name><name><surname>Hyde</surname><given-names>Embriette R.</given-names></name><name><surname>Tyler</surname><given-names>McCue</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders.</article-title>
<source>Cell</source>
<volume>155</volume> (<issue>7</issue>), <fpage>1451</fpage>&#x02013;<lpage>1463</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.11.024</pub-id>
<pub-id pub-id-type="pmid">24315484</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>S. B.</given-names></name><name><surname>Stanton</surname><given-names>T. B.</given-names></name><name><surname>Jensen</surname><given-names>N. S.</given-names></name></person-group> (<year>1995</year>). <article-title>Mitomycin C induction of bacteriophages from serpulina hyodysenteriae and serpulina innocens</article-title>. <source>FEMS Microbiol. Lett.</source>
<volume>134</volume> (<issue>1</issue>), <fpage>97</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.1995.tb07921.x</pub-id>
<pub-id pub-id-type="pmid">8593962</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Yindi</given-names></name><name><surname>Stornetta</surname><given-names>Alessia</given-names></name><name><surname>Villalta</surname><given-names>Peter W.</given-names></name><name><surname>Wilson</surname><given-names>Matthew R.</given-names></name><name><surname>Boudreau</surname><given-names>Paul D.</given-names></name><name><surname>Zha</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Reactivity of an unusual amidase may explain colibactin&#x02019;s DNA cross-linking activity</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>141</volume> (<issue>29</issue>), <fpage>11489</fpage>&#x02013;<lpage>11496</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b02453</pub-id>
<pub-id pub-id-type="pmid">31251062</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kidane</surname><given-names>Dawit</given-names></name><name><surname>Chae</surname><given-names>Wook Jin</given-names></name><name><surname>Czochor</surname><given-names>Jennifer</given-names></name><name><surname>Eckert</surname><given-names>Kristin A.</given-names></name><name><surname>Glazer</surname><given-names>Peter M.</given-names></name><name><surname>Bothwell</surname><given-names>Alfred L. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Interplay between DNA repair and inflammation, and the link to cancer</article-title>. <source>Crit. Rev. Biochem. Mol. Biol.</source>
<volume>49</volume> (<issue>2</issue>), <fpage>116</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.3109/10409238.2013.875514</pub-id>
<pub-id pub-id-type="pmid">24410153</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>Janice J.</given-names></name><name><surname>Bridle</surname><given-names>Byram W.</given-names></name><name><surname>Ghia</surname><given-names>Jean-Eric</given-names></name><name><surname>Wang</surname><given-names>Huaqing</given-names></name><name><surname>Syed</surname><given-names>Shahzad N.</given-names></name><name><surname>Manocha</surname><given-names>Marcus M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation</article-title>. <source>J. Immunol.</source>
<volume>190</volume> (<issue>9</issue>), <fpage>4795</fpage>&#x02013;<lpage>4804</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1201887</pub-id>
<pub-id pub-id-type="pmid">23554310</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kruis</surname><given-names>W.</given-names></name><name><surname>Fric</surname><given-names>P.</given-names></name><name><surname>Pokrotnieks</surname><given-names>J.</given-names></name><name><surname>Luk&#x000e1;s</surname><given-names>M.</given-names></name><name><surname>Fixa</surname><given-names>B.</given-names></name><name><surname>Kasc&#x000e1;k</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine</article-title>. <source>Gut</source>
<volume>53</volume> (<issue>11</issue>), <fpage>1617</fpage>&#x02013;<lpage>1623</lpage>. <pub-id pub-id-type="doi">10.1136/gut.2003.037747</pub-id>
<pub-id pub-id-type="pmid">15479682</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lang</surname><given-names>Michaela</given-names></name><name><surname>Baumgartner</surname><given-names>Maximilian</given-names></name><name><surname>Ro&#x0017c;alska</surname><given-names>Aleksandra</given-names></name><name><surname>Frick</surname><given-names>Adrian</given-names></name><name><surname>Riva</surname><given-names>Alessandra</given-names></name><name><surname>Jarek</surname><given-names>Michael</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of lynch syndrome</article-title>. <source>Int. J. Cancer</source>
<volume>147</volume> (<issue>8</issue>), <fpage>2316</fpage>&#x02013;<lpage>2326</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.33028</pub-id>
<pub-id pub-id-type="pmid">32350866</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>Young-Ju</given-names></name><name><surname>Park</surname><given-names>Su-Jung</given-names></name><name><surname>Ciccone</surname><given-names>Samantha L. M.</given-names></name><name><surname>Kim</surname><given-names>Chong-Rak</given-names></name><name><surname>Lee</surname><given-names>Suk-Hee</given-names></name></person-group> (<year>2006</year>). <article-title>An <italic>in vivo</italic> analysis of MMC-induced DNA damage and its repair</article-title>. <source>Carcinogenesis</source>
<volume>27</volume> (<issue>3</issue>), <fpage>446</fpage>&#x02013;<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgi254</pub-id>
<pub-id pub-id-type="pmid">16258176</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemire</surname><given-names>S&#x000e9;bastien</given-names></name><name><surname>Figueroa-Bossi</surname><given-names>Nara</given-names></name><name><surname>Bossi</surname><given-names>Lionello</given-names></name></person-group> (<year>2011</year>). <article-title>Bacteriophage crosstalk: Coordination of prophage induction by trans-acting antirepressors</article-title>. <source>PLoS Genet.</source>
<volume>7</volume> (<issue>6</issue>), <fpage>e1002149</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002149</pub-id>
<pub-id pub-id-type="pmid">21731505</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Zhi Shan</given-names></name><name><surname>Schmauss</surname><given-names>Claudia</given-names></name><name><surname>Cuenca</surname><given-names>Abigail</given-names></name><name><surname>Ratcliffe</surname><given-names>Elyanne</given-names></name><name><surname>Gershon</surname><given-names>Michael D.</given-names></name></person-group> (<year>2006</year>). <article-title>Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: Analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice</article-title>. <source>J. Neurosci.</source>
<volume>26</volume> (<issue>10</issue>), <fpage>2798</fpage>&#x02013;<lpage>2807</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4720-05.2006</pub-id>
<pub-id pub-id-type="pmid">16525059</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Zhong-Rui</given-names></name><name><surname>Li</surname><given-names>Jie</given-names></name><name><surname>Cai</surname><given-names>Wenlong</given-names></name><name><surname>Lai</surname><given-names>Jennifer Y. H.</given-names></name><name><surname>McKinnie</surname><given-names>Shaun M. K.</given-names></name><name><surname>Zhang</surname><given-names>Wei-Peng</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Macrocyclic colibactin induces DNA double-strand breaks via copper-mediated oxidative cleavage</article-title>. <source>Nat. Chem.</source>
<volume>11</volume> (<issue>10</issue>), <fpage>880</fpage>&#x02013;<lpage>889</lpage>. <pub-id pub-id-type="doi">10.1038/s41557-019-0317-7</pub-id>
<pub-id pub-id-type="pmid">31527851</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Zhong-Rui</given-names></name><name><surname>Li</surname><given-names>Jie</given-names></name><name><surname>Gu</surname><given-names>Jin-Ping</given-names></name><name><surname>Lai</surname><given-names>Jennifer Y. H.</given-names></name><name><surname>Duggan</surname><given-names>Brendan M.</given-names></name><name><surname>Zhang</surname><given-names>Wei-Peng</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Divergent biosynthesis yields a cytotoxic aminomalonate-containing precolibactin</article-title>. <source>Nat. Chem. Biol.</source>
<volume>12</volume> (<issue>10</issue>), <fpage>773</fpage>&#x02013;<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2157</pub-id>
<pub-id pub-id-type="pmid">27547923</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Zhong-Rui</given-names></name><name><surname>Li</surname><given-names>Yongxin</given-names></name><name><surname>Lai</surname><given-names>Jennifer Y. H.</given-names></name><name><surname>Tang</surname><given-names>Jianqiang</given-names></name><name><surname>Wang</surname><given-names>Bin</given-names></name><name><surname>Lu</surname><given-names>Liang</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Critical intermediates reveal new biosynthetic events in the enigmatic colibactin pathway</article-title>. <source>Chembiochem</source>
<volume>16</volume> (<issue>12</issue>), <fpage>1715</fpage>&#x02013;<lpage>1719</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201500239</pub-id>
<pub-id pub-id-type="pmid">26052818</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Little</surname><given-names>John W.</given-names></name><name><surname>Shepley</surname><given-names>Donald P.</given-names></name><name><surname>Wert</surname><given-names>David W.</given-names></name></person-group> (<year>1999</year>). <article-title>Robustness of a gene regulatory circuit</article-title>. <source>EMBO J.</source>
<volume>18</volume> (<issue>15</issue>), <fpage>4299</fpage>&#x02013;<lpage>4307</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/18.15.4299</pub-id>
<pub-id pub-id-type="pmid">10428968</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Little</surname><given-names>John W.</given-names></name><name><surname>Michalowski</surname><given-names>Christine B.</given-names></name></person-group> (<year>2010</year>). <article-title>Stability and instability in the lysogenic state of phage lambda</article-title>. <source>J. Bacteriol.</source>
<volume>192</volume> (<issue>22</issue>), <fpage>6064</fpage>&#x02013;<lpage>6076</lpage>. <pub-id pub-id-type="doi">10.1128/JB.00726-10</pub-id>
<pub-id pub-id-type="pmid">20870769</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luo</surname><given-names>Yi</given-names></name><name><surname>Ruan</surname><given-names>Li-Fang</given-names></name><name><surname>Zhao</surname><given-names>Chang-Ming</given-names></name><name><surname>Wang</surname><given-names>Cheng-Xian</given-names></name><name><surname>Peng</surname><given-names>Dong-Hai</given-names></name><name><surname>Sun</surname><given-names>Ming</given-names></name></person-group> (<year>2011</year>). <article-title>Validation of the intact zwittermicin A biosynthetic gene cluster and discovery of a complementary resistance mechanism in Bacillus thuringiensis</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>55</volume> (<issue>9</issue>), <fpage>4161</fpage>&#x02013;<lpage>4169</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00111-11</pub-id>
<pub-id pub-id-type="pmid">21730118</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madsen</surname><given-names>Jonas Stenl&#x000f8;kke</given-names></name><name><surname>Burm&#x000f8;lle</surname><given-names>Mette</given-names></name><name><surname>Hansen</surname><given-names>Lars Hestbjerg</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>S&#x000f8;ren Johannes</given-names></name></person-group> (<year>2012</year>). <article-title>The interconnection between biofilm formation and horizontal gene transfer</article-title>. <source>FEMS Immunol. Med. Microbiol.</source>
<volume>65</volume> (<issue>2</issue>), <fpage>183</fpage>&#x02013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00960.x</pub-id>
<pub-id pub-id-type="pmid">22444301</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcq</surname><given-names>Ingrid</given-names></name><name><surname>Martin</surname><given-names>Patricia</given-names></name><name><surname>Payros</surname><given-names>Delphine</given-names></name><name><surname>Cuevas-Ramos</surname><given-names>Gabriel</given-names></name><name><surname>Boury</surname><given-names>Mich&#x000e8;le</given-names></name><name><surname>Watrin</surname><given-names>Claude</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The genotoxin colibactin exacerbates lymphopenia and decreases survival rate in mice infected with septicemic Escherichia coli</article-title>. <source>J. Infect. Dis.</source>
<volume>210</volume> (<issue>2</issue>), <fpage>285</fpage>&#x02013;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu071</pub-id>
<pub-id pub-id-type="pmid">24489107</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>Patricia</given-names></name><name><surname>Marcq</surname><given-names>Ingrid</given-names></name><name><surname>Magistro</surname><given-names>Giuseppe</given-names></name><name><surname>Penary</surname><given-names>Marie</given-names></name><name><surname>Garcie</surname><given-names>Christophe</given-names></name><name><surname>Payros</surname><given-names>Delphine</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli</article-title>. <source>PLoS Pathog.</source>
<volume>9</volume> (<issue>7</issue>), <fpage>e1003437</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003437</pub-id>
<pub-id pub-id-type="pmid">23853582</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matos</surname><given-names>R. C.</given-names></name><name><surname>Lapaque</surname><given-names>N.</given-names></name><name><surname>Rigottier-Gois</surname><given-names>L.</given-names></name><name><surname>Debarbieux</surname><given-names>L.</given-names></name><name><surname>Meylheuc</surname><given-names>T.</given-names></name><name><surname>Gonzalez-Zorn</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Enterococcus faecalis prophage dynamics and contributions to pathogenic traits</article-title>. <source>PLoS Genet.</source>
<volume>9</volume> (<issue>6</issue>), <fpage>e1003539</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1003539</pub-id>
<pub-id pub-id-type="pmid">23754962</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Molin</surname><given-names>S&#x000f8;ren</given-names></name><name><surname>Tolker-Nielsen</surname><given-names>Tim</given-names></name></person-group> (<year>2003</year>). <article-title>Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure</article-title>. <source>Curr. Opin. Biotechnol.</source>
<volume>14</volume> (<issue>3</issue>), <fpage>255</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1016/s0958-1669(03)00036-3</pub-id>
<pub-id pub-id-type="pmid">12849777</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moretti</surname><given-names>C.</given-names></name><name><surname>Hosni</surname><given-names>T.</given-names></name><name><surname>Vandemeulebroecke</surname><given-names>K.</given-names></name><name><surname>Brady</surname><given-names>C.</given-names></name><name><surname>De Vos</surname><given-names>P.</given-names></name><name><surname>Buonaurio</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Erwinia Oleae sp. Nov., isolated from olive knots caused by Pseudomonas savastanoi pv. Savastanoi</article-title>. <source>Int. J. Syst. Evol. Microbiol.</source>
<volume>61</volume> (<issue>11</issue>), <fpage>2745</fpage>&#x02013;<lpage>2752</lpage>. <pub-id pub-id-type="doi">10.1099/ijs.0.026336-0</pub-id>
<pub-id pub-id-type="pmid">21186287</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nanda</surname><given-names>Arun M.</given-names></name><name><surname>Thormann</surname><given-names>Kai</given-names></name><name><surname>Julia</surname><given-names>Frunzke</given-names></name></person-group> (<year>2015</year>). <article-title>Impact of spontaneous prophage induction on the fitness of bacterial populations and host-microbe interactions</article-title>. <source>J. Bacteriol.</source>
<volume>197</volume> (<issue>3</issue>), <fpage>410</fpage>&#x02013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1128/jb.02230-14</pub-id>
<pub-id pub-id-type="pmid">25404701</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Neely</surname><given-names>Melody N.</given-names></name><name><surname>Friedman</surname><given-names>David I.</given-names></name></person-group> (<year>1998</year>). <article-title>Arrangement and functional identification of genes in the regulatory region of lambdoid phage H-19B, a carrier of a shiga-like toxin</article-title>. <source>Gene</source>
<volume>223</volume> (<issue>1&#x02013;2</issue>), <fpage>105</fpage>&#x02013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1016/s0378-1119(98)00236-4</pub-id>
<pub-id pub-id-type="pmid">9858702</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nougayr&#x000e8;de</surname><given-names>Jean-Philippe</given-names></name><name><surname>Homburg</surname><given-names>Stefan</given-names></name><name><surname>Taieb</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><name><surname>Boury</surname><given-names>Mich&#x000e8;le</given-names></name><name><surname>Brzuszkiewicz</surname><given-names>Elzbieta</given-names></name><name><surname>Gottschalk</surname><given-names>Gerhard</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Escherichia coli induces DNA double-strand breaks in eukaryotic cells</article-title>. <source>Sci. (New York, N.Y.)</source>
<volume>313</volume> (<issue>5788</issue>), <fpage>848</fpage>&#x02013;<lpage>851</lpage>. <pub-id pub-id-type="doi">10.1126/science.1127059</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olier</surname><given-names>M.</given-names></name><name><surname>Marcq</surname><given-names>I.</given-names></name><name><surname>Salvador-Cartier</surname><given-names>C.</given-names></name><name><surname>Secher</surname><given-names>T.</given-names></name><name><surname>Ulrich</surname><given-names>D.</given-names></name><name><surname>Boury</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Genotoxicity of Escherichia coli Nissle 1917 strain cannot Be dissociated from its probiotic activity</article-title>. <source>Gut Microbes</source>
<volume>3</volume> (<issue>6</issue>), <fpage>501</fpage>&#x02013;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.4161/gmic.21737</pub-id>
<pub-id pub-id-type="pmid">22895085</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pericone</surname><given-names>Christopher D.</given-names></name><name><surname>Park</surname><given-names>Sunny</given-names></name><name><surname>James</surname><given-names>A. Imlay</given-names></name><name><surname>Weiser</surname><given-names>Jeffrey N.</given-names></name></person-group> (<year>2003</year>). <article-title>Factors contributing to hydrogen peroxide resistance in Streptococcus pneumoniae include pyruvate oxidase (SpxB) and avoidance of the toxic effects of the fenton reaction</article-title>. <source>J. Bacteriol.</source>
<volume>185</volume> (<issue>23</issue>), <fpage>6815</fpage>&#x02013;<lpage>6825</lpage>. <pub-id pub-id-type="doi">10.1128/jb.185.23.6815-6825.2003</pub-id>
<pub-id pub-id-type="pmid">14617646</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pleguezuelos-Manzano</surname><given-names>Cayetano</given-names></name><name><surname>Puschhof</surname><given-names>Jens</given-names></name><name><surname>Arne van Hoeck</surname></name><name><surname>Wood</surname><given-names>Henry M.</given-names></name><name><surname>Nomburg</surname><given-names>Jason</given-names></name><name><surname>Gurjao</surname><given-names>Carino.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Mutational signature in colorectal cancer caused by genotoxic Pks+ E. Coli</article-title>. <source>Nature</source>
<volume>580</volume> (<issue>7802</issue>), <fpage>269</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2080-8</pub-id>
<pub-id pub-id-type="pmid">32106218</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reuter</surname><given-names>Christian</given-names></name><name><surname>Alzheimer</surname><given-names>Mona</given-names></name><name><surname>Walles</surname><given-names>Heike</given-names></name><name><surname>Oelschlaeger</surname><given-names>Tobias A.</given-names></name></person-group> (<year>2018</year>). <article-title>An adherent mucus layer attenuates the genotoxic effect of colibactin</article-title>. <source>Cell. Microbiol.</source>
<volume>20</volume> (<issue>2</issue>), <fpage>e12812</fpage>. <pub-id pub-id-type="doi">10.1111/cmi.12812</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rice</surname><given-names>Scott A.</given-names></name><name><surname>Tan</surname><given-names>Chuan Hao</given-names></name><name><surname>Kung</surname><given-names>Vanderlene</given-names></name><name><surname>Woo</surname><given-names>Jerry</given-names></name><name><surname>Tay</surname><given-names>Martin</given-names></name><name><surname>Hauser</surname><given-names>Alan</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage</article-title>. <source>ISME J.</source>
<volume>3</volume> (<issue>3</issue>), <fpage>271</fpage>&#x02013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/ismej.2008.109</pub-id>
<pub-id pub-id-type="pmid">19005496</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robinson</surname><given-names>Cory M.</given-names></name><name><surname>Sinclair</surname><given-names>James F.</given-names></name><name><surname>Smith</surname><given-names>Michael J.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>Alison D.</given-names></name></person-group> (<year>2006</year>). <article-title>Shiga toxin of enterohemorrhagic Escherichia coli type O157: H7 promotes intestinal colonization</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>103</volume> (<issue>25</issue>), <fpage>9667</fpage>&#x02013;<lpage>9672</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0602359103</pub-id>
<pub-id pub-id-type="pmid">16766659</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schultz</surname><given-names>Michael</given-names></name></person-group> (<year>2008</year>). <article-title>Clinical use of E. Coli Nissle 1917 in inflammatory bowel disease</article-title>. <source>Inflamm. Bowel Dis.</source>
<volume>14</volume> (<issue>7</issue>), <fpage>1012</fpage>&#x02013;<lpage>1018</lpage>. <pub-id pub-id-type="doi">10.1002/ibd.20377</pub-id>
<pub-id pub-id-type="pmid">18240278</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Selva</surname><given-names>Laura</given-names></name><name><surname>Viana</surname><given-names>David</given-names></name><name><surname>Regev-Yochay</surname><given-names>Gili</given-names></name><name><surname>Trzcinski</surname><given-names>Krzysztof</given-names></name><name><surname>Lasa</surname><given-names>Inigo</given-names></name><name><surname>Novick</surname><given-names>Richard P.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Killing niche competitors by remote-control bacteriophage induction</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>106</volume> (<issue>4</issue>), <fpage>1234</fpage>&#x02013;<lpage>1238</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809600106</pub-id>
<pub-id pub-id-type="pmid">19141630</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seo</surname><given-names>Ho Seong</given-names></name><name><surname>Xiong</surname><given-names>Yan Q.</given-names></name><name><surname>Mitchell</surname><given-names>Jennifer</given-names></name><name><surname>Seepersaud</surname><given-names>Ravin</given-names></name><name><surname>Bayer</surname><given-names>Arnold S.</given-names></name><name><surname>Sullam</surname><given-names>Paul M.</given-names></name></person-group> (<year>2010</year>). <article-title>Bacteriophage lysin mediates the binding of Streptococcus mitis to human platelets through interaction with fibrinogen</article-title>. <source>PLoS Pathog.</source>
<volume>6</volume> (<issue>8</issue>), <fpage>e1001047</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1001047</pub-id>
<pub-id pub-id-type="pmid">20714354</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharon</surname><given-names>Gil</given-names></name><name><surname>Garg</surname><given-names>Neha</given-names></name><name><surname>Debelius</surname><given-names>Justine</given-names></name><name><surname>Knight</surname><given-names>Rob</given-names></name><name><surname>Dorrestein</surname><given-names>Pieter C.</given-names></name><name><surname>Mazmanian</surname><given-names>Sarkis K.</given-names></name></person-group> (<year>2014</year>). <article-title>Specialized metabolites from the microbiome in health and disease</article-title>. <source>Cell Metab.</source>
<volume>20</volume> (<issue>5</issue>), <fpage>719</fpage>&#x02013;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.10.016</pub-id>
<pub-id pub-id-type="pmid">25440054</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silpe</surname><given-names>Justin E.</given-names></name><name><surname>Joel</surname><given-names>W. H.</given-names></name><name><surname>Wong</surname><given-names>Si&#x000e2;n V. Owen</given-names></name><name><surname>Balskus</surname><given-names>Emily P.</given-names></name><name><surname>Balskus</surname><given-names>E. P.</given-names></name></person-group> (<year>2022</year>). <article-title>The bacterial toxin colibactin triggers prophage induction</article-title>. <source>Nature</source>
<volume>603</volume> (<issue>7900</issue>), <fpage>315</fpage>&#x02013;<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-04444-3</pub-id>
<pub-id pub-id-type="pmid">35197633</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>Jian-Wei</given-names></name><name><surname>Liu</surname><given-names>Xin</given-names></name><name><surname>Ye</surname><given-names>Wei</given-names></name><name><surname>Li</surname><given-names>Zhong-rui</given-names></name><name><surname>Qian</surname><given-names>Pei-Yuan</given-names></name></person-group> (<year>2022</year>). <article-title>Biosynthesis and bioactivities of microbial genotoxin colibactins</article-title>. <source>Nat. Product. Rep.</source>
<volume>39</volume> (<issue>5</issue>), <fpage>991</fpage>&#x02013;<lpage>1014</lpage>. <pub-id pub-id-type="doi">10.1039/D1NP00050K</pub-id>
</mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thomason</surname><given-names>Lynn C.</given-names></name><name><surname>Schiltz</surname><given-names>Carl J.</given-names></name><name><surname>Court</surname><given-names>Carolyn</given-names></name><name><surname>Hosford</surname><given-names>Christopher J.</given-names></name><name><surname>Chappie</surname><given-names>Myfanwy C. Adams, Joshua S.</given-names></name><name><surname>Court</surname><given-names>Donald L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Bacteriophage &#x003bb; RexA and RexB functions assist the transition from lysogeny to lytic growth</article-title>. <source>Mol. Microbiol.</source>
<volume>116</volume> (<issue>4</issue>), <fpage>1044</fpage>&#x02013;<lpage>1063</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14792</pub-id>
<pub-id pub-id-type="pmid">34379857</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tichenor</surname><given-names>Mark S.</given-names></name><name><surname>Boger</surname><given-names>Dale L.</given-names></name></person-group> (<year>2008</year>). <article-title>Yatakemycin: Total synthesis, DNA alkylation, and biological properties</article-title>. <source>Nat. Prod. Rep.</source>
<volume>25</volume> (<issue>2</issue>), <fpage>220</fpage>&#x02013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1039/b705665f</pub-id>
<pub-id pub-id-type="pmid">18389136</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>Prabhanshu</given-names></name><name><surname>Shine</surname><given-names>Emilee E.</given-names></name><name><surname>Healy</surname><given-names>Alan R.</given-names></name><name><surname>Kim</surname><given-names>Chung Sub</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name><name><surname>Bruner</surname><given-names>Steven D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>ClbS is a cyclopropane hydrolase that confers colibactin resistance</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>139</volume> (<issue>49</issue>), <fpage>17719</fpage>&#x02013;<lpage>17722</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.7b09971</pub-id>
<pub-id pub-id-type="pmid">29112397</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tronnet</surname><given-names>Sophie</given-names></name><name><surname>Floch</surname><given-names>Pauline</given-names></name><name><surname>Lucarelli</surname><given-names>Laetitia</given-names></name><name><surname>Gaillard</surname><given-names>Deborah</given-names></name><name><surname>Martin</surname><given-names>Patricia</given-names></name><name><surname>Serino</surname><given-names>Matteo</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The genotoxin colibactin shapes gut microbiota in mice</article-title>. <source>MSphere</source>
<volume>5</volume> (<issue>4</issue>), <fpage>e00589</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/mSphere.00589-20</pub-id>
<pub-id pub-id-type="pmid">32611705</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ullman</surname><given-names>Thomas A.</given-names></name><name><surname>Itzkowitz</surname><given-names>Steven H.</given-names></name></person-group> (<year>2011</year>). <article-title>Intestinal inflammation and cancer</article-title>. <source>Gastroenterology</source>
<volume>140</volume> (<issue>6</issue>), <fpage>1807</fpage>&#x02013;<lpage>1816</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2011.01.057</pub-id>
<pub-id pub-id-type="pmid">21530747</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>Maria I.</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name></person-group> (<year>2015</year>). <article-title>The colibactin warhead crosslinks DNA</article-title>. <source>Nat. Chem.</source>
<volume>7</volume> (<issue>5</issue>), <fpage>411</fpage>&#x02013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2221</pub-id>
<pub-id pub-id-type="pmid">25901819</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>Maria I.</given-names></name><name><surname>Engel</surname><given-names>Philipp</given-names></name><name><surname>Trautman</surname><given-names>Eric</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name><name><surname>Crawford</surname><given-names>J. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparative metabolomics and structural characterizations illuminate colibactin pathway-dependent small molecules</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>136</volume> (<issue>26</issue>), <fpage>9244</fpage>&#x02013;<lpage>9247</lpage>. <pub-id pub-id-type="doi">10.1021/ja503450q</pub-id>
<pub-id pub-id-type="pmid">24932672</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waldor</surname><given-names>Matthew K.</given-names></name><name><surname>Mekalanos</surname><given-names>John J.</given-names></name></person-group> (<year>1996</year>). <article-title>Lysogenic conversion by a filamentous phage encoding cholera toxin</article-title>. <source>Science</source>
<volume>272</volume> (<issue>5270</issue>), <fpage>1910</fpage>&#x02013;<lpage>1914</lpage>. <pub-id pub-id-type="doi">10.1126/science.272.5270.1910</pub-id>
<pub-id pub-id-type="pmid">8658163</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walsh</surname><given-names>Christopher T.</given-names></name></person-group> (<year>2004</year>). <article-title>Polyketide and nonribosomal peptide antibiotics: Modularity and versatility</article-title>. <source>Sci. (New York, N.Y.)</source>
<volume>303</volume> (<issue>5665</issue>), <fpage>1805</fpage>&#x02013;<lpage>1810</lpage>. <pub-id pub-id-type="doi">10.1126/science.1094318</pub-id>
</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Xiaoxue</given-names></name><name><surname>Kim</surname><given-names>Younghoon</given-names></name><name><surname>Ma</surname><given-names>Qun</given-names></name><name><surname>Hong</surname><given-names>Seok Hoon</given-names></name><name><surname>Pokusaeva</surname><given-names>Karina</given-names></name><name><surname>Sturino</surname><given-names>Joseph M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Cryptic prophages help bacteria cope with adverse environments</article-title>. <source>Nat. Commun.</source>
<volume>1</volume> (<issue>1</issue>), <fpage>147</fpage>&#x02013;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1038/ncomms1146</pub-id>
<pub-id pub-id-type="pmid">21266997</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wernke</surname><given-names>Kevin M.</given-names></name><name><surname>Xue</surname><given-names>Mengzhao</given-names></name><name><surname>Tirla</surname><given-names>Alina</given-names></name><name><surname>Kim</surname><given-names>Chung Sub</given-names></name><name><surname>Crawford</surname><given-names>Jason M.</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure and bioactivity of colibactin</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<volume>30</volume> (<issue>15</issue>), <fpage>127280</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127280</pub-id>
<pub-id pub-id-type="pmid">32527463</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>Peyton C.</given-names></name><name><surname>Wernke</surname><given-names>Kevin M.</given-names></name><name><surname>Tirla</surname><given-names>Alina</given-names></name><name><surname>Herzon</surname><given-names>Seth B.</given-names></name></person-group> (<year>2020</year>). <article-title>Employing chemical synthesis to study the structure and function of colibactin, a &#x02018;dark matter&#x02019; metabolite</article-title>. <source>Nat. Prod. Rep.</source>
<volume>37</volume> (<issue>11</issue>), <fpage>1532</fpage>&#x02013;<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.1039/d0np00072h</pub-id>
<pub-id pub-id-type="pmid">33174565</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>Matthew R.</given-names></name><name><surname>Jiang</surname><given-names>Yindi</given-names></name><name><surname>Villalta</surname><given-names>Peter W.</given-names></name><name><surname>Stornetta</surname><given-names>Alessia</given-names></name><name><surname>Boudreau</surname><given-names>Paul D.</given-names></name><name><surname>Carr&#x000e1;</surname><given-names>Andrea</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The human gut bacterial genotoxin colibactin alkylates DNA</article-title>. <source>Science</source>
<volume>363</volume> (<issue>6428</issue>), <fpage>eaar7785</fpage>. <pub-id pub-id-type="doi">10.1126/science.aar7785</pub-id>
<pub-id pub-id-type="pmid">30765538</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>Matthew R.</given-names></name><name><surname>Zha</surname><given-names>Li</given-names></name><name><surname>Balskus</surname><given-names>Emily P.</given-names></name></person-group> (<year>2017</year>). <article-title>Natural product discovery from the human microbiome</article-title>. <source>J. Biol. Chem.</source>
<volume>292</volume> (<issue>21</issue>), <fpage>8546</fpage>&#x02013;<lpage>8552</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R116.762906</pub-id>
<pub-id pub-id-type="pmid">28389564</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xue</surname><given-names>Mengzhao</given-names></name><name><surname>Kim</surname><given-names>Chung Sub</given-names></name><name><surname>Healy</surname><given-names>Alan R.</given-names></name><name><surname>Wernke</surname><given-names>Kevin M.</given-names></name><name><surname>Wang</surname><given-names>Zhixun</given-names></name><name><surname>Frischling</surname><given-names>Madeline C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Structure elucidation of colibactin and its DNA cross-links</article-title>. <source>Science</source>
<volume>365</volume> (<issue>6457</issue>), <fpage>eaax2685</fpage>. <pub-id pub-id-type="doi">10.1126/science.aax2685</pub-id>
<pub-id pub-id-type="pmid">31395743</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zha</surname><given-names>Yuguo</given-names></name><name><surname>Chong</surname><given-names>Hui</given-names></name><name><surname>Yang</surname><given-names>Pengshuo</given-names></name><name><surname>Kang</surname><given-names>Ning</given-names></name></person-group> (<year>2022</year>). <article-title>Microbial dark matter: From discovery to applications</article-title>. <source>Genomics Proteomics Bioinforma.</source>
<volume>S1672-0229</volume> (<issue>22</issue>), <fpage>00037</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.gpb.2022.02.007</pub-id>
</mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Tao</given-names></name><name><surname>Hirayama</surname><given-names>Yuichiro</given-names></name><name><surname>Tsunematsu</surname><given-names>Yuta</given-names></name><name><surname>Suzuki</surname><given-names>Nanami</given-names></name><name><surname>Tanaka</surname><given-names>Seiji</given-names></name><name><surname>Uchiyama</surname><given-names>Nahoko</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Isolation of new colibactin metabolites from wild-type Escherichia coli and <italic>in situ</italic> trapping of a mature colibactin derivative</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>143</volume> (<issue>14</issue>), <fpage>5526</fpage>&#x02013;<lpage>5533</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.1c01495</pub-id>
<pub-id pub-id-type="pmid">33787233</pub-id></mixed-citation></ref></ref-list></back></article>